A Biological Alignment Framework for Interpreting Anti-Inflammatory Cardiovascular Trials in Atherosclerosis.

Area of Science:

• Cardiovascular Research
• Immunology
• Translational Medicine

Background:

• The inflammatory hypothesis of atherosclerosis has led to clinical trials with varied outcomes.
• A structured framework is needed to understand inconsistent results from anti-inflammatory therapies.

Purpose of the Study:

• To develop and apply a translational framework for analyzing anti-inflammatory cardiovascular trial outcomes.
• To explain the heterogeneity in clinical trial results by evaluating biological alignment.

Main Methods:

• Conducted a narrative review of randomized controlled trials, Mendelian randomization studies, and mechanistic investigations.
• Searched PubMed, EMBASE, and Cochrane databases through December 2024.
• Analyzed trial outcomes using four alignment domains: pathway specificity, target engagement, patient selection, and endpoint matching, calculating a Total Alignment Score (TAS).

Main Results:

• High biological alignment (TAS 8/8, e.g., CANTOS) correlated with robust clinical benefit.
• Partial alignment (TAS 6/8, e.g., COLCOT, LoDoCo2) showed modest effects.
• Low alignment (TAS 4/8, e.g., CIRT) was associated with neutral results.
• Aging processes like inflammaging and immunosenescence impact alignment domains.

Conclusions:

• The Biological Alignment Model provides a framework for interpreting divergent anti-inflammatory cardiovascular trial outcomes.
• This model enables iterative trial refinement and the design of precision immunotherapy strategies for atherosclerosis.
• Systematic characterization by biological alignment explains clinical trial heterogeneity.